Cancer biologics Market Report 2026

The cancer biologics market size has grown strongly in recent years. It will grow from $129.05 billion in 2025 to $140.88 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to increasing global cancer prevalence, rising demand for advanced cancer therapies, growing oncology research activities, limited effectiveness of conventional chemotherapy, expansion of hospital-based cancer treatment centers.

The cancer biologics market size is expected to see strong growth in the next few years. It will grow to $203.29 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to advancements in cell and gene therapy platforms, increasing approvals of novel biologics, growth in personalized oncology treatments, rising investment in cancer biologics R&D, expansion of biologics manufacturing capacity. Major trends in the forecast period include rising adoption of immunotherapy and targeted biologic treatments, increasing use of monoclonal antibodies in oncology, growth of cell and gene therapy-based cancer treatments, expansion of cancer vaccine development programs, rising focus on combination biologic therapies.

The increasing prevalence of chronic diseases is one of the key factors driving the growth of the cancer biologics market. Chronic diseases are long-lasting conditions that persist over extended periods and often impair overall health and quality of life, with cancer being among the most common chronic illnesses. The most frequently diagnosed cancers include breast cancer, lung and bronchus cancer, prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer, non-Hodgkin lymphoma, kidney and renal pelvis cancer, endometrial cancer, leukemia, pancreatic cancer, thyroid cancer, and liver cancer. For example, in February 2024, according to reports published by the Centers for Disease Control and Prevention, a US-based public health agency, a growing proportion of people in the United States are living with multiple chronic conditions, with 42% managing two or more chronic diseases and 12% living with five or more. Therefore, the rising burden of chronic diseases is expected to drive the growth of the cancer biologics market in the coming years.

Major companies operating in the cancer biologics market are concentrating on the development of advanced therapies such as bispecific antibodies and biomarker-guided biologics to improve treatment effectiveness and more precisely target cancer cells. Bispecific antibodies are next-generation biologic therapies capable of binding to two different targets at the same time, while biomarker-guided biologics are designed to selectively attack tumor cells identified through specific molecular markers. For instance, in November 2024, Jazz Pharmaceuticals Public Limited Company, a Dublin-based biopharmaceutical company, received accelerated approval from the U.S. Food and Drug Administration for Ziihera (zanidatamab hrii) for adults with previously treated, unresectable, or metastatic HER2-positive (IHC 3+) biliary tract cancer. This approval represented the first and only dual HER2-targeted bispecific antibody approved for this indication, extending the application of HER2-targeted biologic therapies beyond traditional tumor types.

In February 2025, BioNTech SE, a Germany-based developer of mRNA immunotherapies, cancer vaccines, and bispecific antibody treatments, acquired Biotheus Inc. for an upfront payment of $800 million, with additional milestone payments of up to $150 million. Through this acquisition, BioNTech aimed to strengthen its oncology strategy by obtaining full global rights to Biotheus’s bispecific antibody platform, including BNT327/PM8002, and by expanding its research, development, and manufacturing capabilities. Biotheus Inc. is a China-based clinical-stage biotechnology company focused on the discovery and development of novel antibody therapies for cancer and inflammatory diseases.

Major companies operating in the cancer biologics market are AbbVie Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Eli Lilly and Company, AmgenInc., Bristol-Myers Squibb Company, Johnson & Johnson, Merck & Co.Inc., Novartis AG, Pfizer Inc., Celgene Corporation, Daiichi Sankyo Company Ltd., Seagen Inc., Takeda Pharmaceutical Company Limited, Biogen Inc., Vertex Pharmaceuticals Incorporated, Incyte Corporation, Karyopharm Therapeutics Inc., Kyowa Kirin Co Ltd., Ipsen Biopharmaceuticals Inc., Bayer AG, Biocon Limited, Genentech Inc., Gilead Sciences Inc., Puma Biotechnology, Regeneron Pharmaceuticals Inc.

North America was the largest region in the cancer biologics market in 2025. The Middle East is expected to be the fastest-growing region in the global cancer biologics market share during the forecast period. The regions covered in the cancer biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cancer biologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the cancer biologics market by increasing the cost of imported biologic raw materials, specialized manufacturing equipment, and cold-chain logistics components. High-cost segments such as monoclonal antibodies and cell and gene therapies are most affected, particularly in regions like North America and Europe that depend on global supply chains. These cost pressures have influenced pricing and accessibility of advanced cancer biologics. However, tariffs have also encouraged domestic production, localized manufacturing investments, and innovation in cost-efficient biologic development processes.

The cancer biologics market research report is one of a series of new reports that provides cancer biologics market statistics, including cancer biologics industry global market size, regional shares, competitors with a cancer biologics market share, detailed cancer biologics market segments, market trends and opportunities, and any further data you may need to thrive in the cancer biologics industry. This cancer biologics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cancer biologics refer to substances derived from living organisms or their byproducts that are used in the prevention, detection, or treatment of cancer and other diseases. Examples of biologic agents include immunoglobulins, interleukins, and vaccines. Biological therapy is a type of cancer treatment that utilizes the body’s immune system to identify and destroy cancer cells.

The primary types of cancer biologics include monoclonal antibodies, vaccines, cell and gene therapy, and others. Monoclonal antibodies are produced by cloning a single white blood cell, and each antibody generated through this process originates from one parent cell. These biologics are used in the treatment of non-small cell lung cancer, prostate cancer, breast cancer, acute myeloid leukemia, lymphoma, multiple myeloma, ovarian cancer, colorectal cancer, gastric cancer, and others, and are distributed through channels such as hospitals, clinics, and others.

The cancer biologics market consists of sales of cancer vaccines, cytokine therapy, and angiogenesis inhibitors. Values in this market are factory gate values which are the values of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.